MultiVu Video Feed: SCIELE PHARMA ANNOUNCES AVAILABILITY OF ULESFIA(TM), FIRST AND ONLY FDA-APPROVED NON-NEUROTOXIC HEAD LICE TREATMENT Sciele
Pharma, Inc., a Shionogi Company, today announced the availability
of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription
medication that kills head lice by asphyxiation without potential neurotoxic
side effects. Approved by the U.S. Food & Drug Administration (FDA),...
Upsher-Smith Laboratories, Inc. Updates Prenexa.com with Folic Acid Content, Money-Saving Coupon, and Personalized Address Labels
1. PreNexa package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc; 2008.
2. Prenate DHA package insert. Atlanta, GA: sciele
Pharma, Inc; 2007.
3. PrimaCare One package insert. St Louis, MO: Ther-Rx Corporation; 2007.
4. Neevo DHA package insert. Covington, LA: Pamlab, LLC...
Omega-3 Fatty Acids Key to Fetal Development - Possible Mercury Contamination Concerns in Some Fish Oil Avoided With Plant-based DHA in PreNexa(R) Prenatal Vitamins
...her-Smith Laboratories, Inc; 2008. 11 . Neevo DHA [package insert]. Covington, LA: PamLab LLC; 2009. 12 . Prenate DHA [package insert]. Atlanta, GA: sciele
Pharma, Inc; 2007. 13. American Pregnancy Association. Pregnancy and Constipation. http://www.americanpregnancy.org/pregnancyhealth/constipation....
Upsher-Smith Laboratories Launches Prenexa.com to Support Prenatal Nutrition and Health
...macal Company; 2007.
3. Duet DHAec (package insert). Newport, KY: Xanodyne Pharmaceuticals, Inc; 2007.
4. Prenate DHA (package insert). Atlanta, GA: sciele
Pharma, Inc; 2007.
5. PrimaCare Advantage (package insert). St. Louis, MO: Ther-Rx Corporation; 2008.
6. PrimaCare One (package insert). St. Louis, ...
First and Only Single Capsule Daily Rx Prenatal Vitamin With Plant-Based DHA Now Available
...cal Company; 2007. 3. Duet DHA(ec) (package insert). Newport,
KY: Xanodyne Pharmaceuticals, Inc; 2007. 4. Prenate DHA (package insert).
Atlanta, GA: sciele
Pharma, Inc; 2007. 5. PrimaCare Advantage (package
insert). St. Louis, MO: Ther-Rx Corporation; 2008. 6. PrimaCare One (package
insert). St. Louis, ...
QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...c (Nasdaq: HGSI ) Vical, Inc (Nasdaq: VICL ) Add Mitsubishi Tanabe Pharma Corporation (TSE: 4508) Sangamo BioSciences Inc (Nasdaq: SGMO ) sciele
Pharma, Inc. (Nasdaq: SCRX )
Composite Index (HHQ) Drop Advanced Medical Optics, Inc. (NYSE: EYE ) Align Technology Inc. (Nasdaq: ALGN ) A...
Sciele in Medical Technology
SkyePharma and Sciele Pharma Announce Successful Completion of New
Sular Formulation Clinical Trial Programme
Study Showed Bioequivalence
LONDON, UK and ATLANTA, US, May 14, 2007 - SkyePharma PLC
(LSE:SKP; NASDAQ:SKYE) and Sciele
Pharma. Inc. (NASDAQ:SCRX) today
announce the successful completion of the clinical trial programme
for the new formulation of Sular, a calcium
channel blocking agent for the ...
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
... and as an add-on therapy to stimulant medication for children and adolescents with ADHD. The North American rights to market Clonicel are licensed to sciele
Pharma, a Shionogi Company, which is an Atlanta-based specialty pharmaceutical company.
"Our data from the first phase 3 study strongly suggest t...
Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
...filed for CloniBID with FDA review expected by the end of the year.
Commercial rights to both drugs, and to ADX415, have been granted to
Pharma, a Shionogi Company.
About Addrenex Pharmaceuticals, Inc.
Addrenex Pharmaceuticals is a focused specialty pharmaceutical company
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
eight weeks at one of 13 study centers nationwide.
If Clonicel is approved by the Food and Drug Administration, the new
drug will be marketed by sciele
Pharma under an agreement signed with
Addrenex in July 2007.
The introduction of Clonicel into the ADHD market would fill a void
that currently exis...
Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
... trials. Commercial rights to both
drugs have been granted to Atlanta-based sciele
The additions of Steven Butts, M.B.A., as vice president of comme... growing clinical program.
"We now have a solid partnership in place with sciele
that will enable
us to develop our lead compounds and to pursue additional ...
Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
...e), Novartis/Nordic Bioscience - Generx(TM), (Coronary artery disease), Cardium Therapeutics - fenofibrate and pravastatin, (Mixed dyslipidemia), sciele
The Five Most Promising Drugs Entering Phase II Trials - VSF-173, (Excessive sleepiness), Vanda Pharmaceuticals - APD-125, (...
Sciele Pharma Announces Successful Completion of New Sular
Formulation Clinical Trial Program
...tion by end of the second
quarter of 2007.
Pharma, Inc. is a pharmaceutical company specializ...the Securities and
Joseph T. Schepers, 678-341-1401
Sciele in Biological Technology
Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex
Pharmaceuticals set it sights on building a new class of drugs to regulate
"adrenergic excess," the small Durham company has signed its second major
deal with Sciele
Pharma, this time to co-develop a new compound for
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
PRINCETON, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Novo Nordisk Inc.
announced today that it has signed an exclusive agreement with Sciele
Pharma, Inc. to market Prandin(R) (repaglinide). Under the terms of the
will exclusively market Prandin(R) and, upon approval by
the US F...
Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
...tended-release (ER) Tablets, 20 mg, 30 mg and 40 mg.
Nisoldipine ER Tablets, indicated for the treatment of hypertension,
are the generic version of sciele
Pharma's Sular(R) ER Tablets, which had
annual U.S. sales of approximately $94 million for the 12 months ending
March 31, 2008, for these three streng...
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...ARMACEUTICALS INC (NASDAQ: MNTA ) NUVELO INC (NASDAQ: NUVO ) PAR PHARMACEUTICAL COS INC. (NYSE: PRX ) SANGAMO BIOSCIENCES INC. (NASDAQ: SGMO ) sciele
PHARMA INC. (NASDAQ: SCRX ) SPEEDEL HOLDING AG-REG (SWX, Switzerland: SPPN)
ABRAXIS BIOSCIENCE INC (NASDAQ: ABII ) BIOMARIN PHARMACEUTICAL...
Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention
...Atlanta Center for Medical Research 3. Celtaxsys 4. ICON Medical Corp. 5. Optima Chemical 6. St Joseph's Translational Research Institute 7. sciele
Pharma 8. Solvay Pharmaceuticals 9. UCB, Inc.* 10. Zygogen
Research Institutions 1. Emory* 2. Georgia Tech 3. Georgia State 4. Universi...
QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
... Inc (Nasdaq: HGSI ) Vical, Inc. (Nasdaq: VICL ) Add Mitsubishi Tanabe Pharma Corporation (TSE: 4508) Sangamo BioSciences Inc. (Nasdaq: SGMO ) sciele
Pharma, Inc. (Nasdaq: SCRX )
Composite Index (HHQ) Drop Advanced Medical Optics, Inc. (NYSE: EYE ) Align Technology Inc. (Nasdaq: ALGN ) Arra...
Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
...Administration, Addrenex and its licensing partner sciele
Pharma, Inc. will
launch the drug in the first hal...r an
additional $11 million in milestone payments. sciele
also holds the first
right of refusal to market Ad...cular and metabolic diseases.
The agreement with sciele
in June was followed by a second contract in